10-Q: Stemtech Corp. Reports Q2 2026 Results Amidst Financial Challenges

Stemtech Corporation's Q2 2026 Form 10-Q reveals a significant decline in net sales and continued net losses, highlighting ongoing financial pressures and operational constraints.

Summary

• Stemtech Corporation filed its Form 10-Q for the quarterly period ended June 30, 2026.
• The company reported a net loss of $292,358 for the three months ended June 30, 2026, compared to a net loss of $296,280 for the same period in 2025.
• For the six months ended June 30, 2026, the net loss was $1,453,418, an improvement from $1,755,006 in the prior year period.
• Net sales decreased by 9.8% to $629,312 for the three months ended June 30, 2026, and by 30.2% to $1,092,269 for the six months ended June 30, 2026.
• The company has a working capital deficit of $10,541,731 as of June 30, 2026, raising substantial doubt about its ability to continue as a going concern.
• Management plans to raise additional capital through equity or debt securities, factoring arrangements, and director loans.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as negative due to continued net losses, a significant working capital deficit, and a substantial decrease in net sales, indicating ongoing financial challenges and operational headwinds.

Positives

• Operating loss improved for both the three-month period ($125,567 in Q2 2026 vs. $300,988 in Q2 2025) and the six-month period ($1,127,996 in H1 2026 vs. $1,505,893 in H1 2025).
• Total operating expenses decreased significantly, by $261,764 for the three months and $830,197 for the six months, due to cost management initiatives.
• Interest expense decreased by $114,702 for the six-month period ended June 30, 2026, compared to the same period in 2025.
• The company launched the Stemtech BioSciences e-commerce retail platform in February 2026 to diversify revenue streams.

Negatives

• Net sales decreased by 9.8% to $629,312 for the three months ended June 30, 2026, and by 30.2% to $1,092,269 for the six months ended June 30, 2026.
• The company reported a net loss of $292,358 for the three months ended June 30, 2026, and $1,453,418 for the six months ended June 30, 2026.
• A significant working capital deficit of $10,541,731 as of June 30, 2026, raises substantial doubt about the company's ability to continue as a going concern.
• Gross margin decreased to 74.0% for the three months ended June 30, 2026, from 79.1% in the prior year period, due to a less favorable product mix and fixed fulfillment costs.
• The company continues to rely on debt and equity financing, with a significant portion of convertible debt being converted to equity, leading to dilution.

Risks

• The company has experienced recurring net losses and negative cash flows from operations since inception and has an accumulated deficit of approximately $36.3 million and a working capital deficiency of approximately $10.5 million at June 30, 2026, raising substantial doubt about the Company's ability to continue as a going concern.
• The company will continue to require substantial funds to implement its new investment acquisition plans.
• The company's ability to continue as a going concern for the next twelve months depends on its ability to execute its business plan, increase revenue, and reduce expenditures.
• The lender for the Leviston Resources, LLC senior secured convertible facility retains full discretion over future funding, and there is no assurance that the remaining facility capacity will be made available.
• Additional issuances of equity or convertible debt securities will result in dilution to current shareholders.
• The company was in default under certain Merchant Cash Advance (MCA) financing agreements, with lenders filing legal proceedings.
• A lawsuit alleging unpaid salary and vacation pay for approximately $267,000 remains ongoing.

Future Outlook

The company expects to require additional capital to meet its long-term operating requirements and plans to raise this through equity or debt securities, factoring arrangements, and director loans. Management anticipates a gradual recovery in sales volume as inventory levels are replenished.

Management Comments

• Management expects the e-commerce platform to contribute to revenue diversification in future periods.
• Management anticipates a gradual recovery in sales volume as inventory levels are replenished.
• Management believes the terms of related-party transactions were reasonable given the Company's financial condition and represent the most practical sources of capital.
• Management believes the resolution of the former CEO's lawsuit will not have a material adverse impact on the Company's consolidated financial position or results of operations.

Industry Context

StockSavvy.ai notes that Stemtech operates in the stem cell nutrition and network marketing sector, a niche that has seen evolving consumer interest. The launch of an e-commerce platform aligns with broader industry trends towards direct-to-consumer sales and digital engagement, potentially offering a path to diversify revenue beyond traditional multi-level marketing models.

Comparison to Industry Standards

• The company's gross margin of 74.0% for the three months ended June 30, 2026, is lower than the 79.1% reported in the prior year, suggesting potential pressure on pricing or increased cost of goods sold relative to sales.
• The significant decrease in net sales (30.2% for the six-month period) indicates challenges in market penetration or product availability that may be more pronounced than for competitors with more stable supply chains.
• The company's reliance on convertible debt and ongoing equity issuances for funding is common among early-stage or distressed companies but contrasts with more established players who may have access to traditional bank financing or stronger cash flow generation.

Legal Proceedings

• A lawsuit filed by the former CEO for approximately $267,000 alleging unpaid salary and vacation pay related to a period prior to 2018 remains ongoing, despite the dismissal of the former CEO's request for summary judgment.
• The company is in default under certain Merchant Cash Advance (MCA) financing agreements, with lenders filing legal proceedings seeking recovery of outstanding balances.

Related Party Transactions

• Outstanding related-party convertible promissory notes with principal balances of $171,475 and $25,000 payable to President and COO John W. Meyer and Director Darryl V. Green, respectively, as of June 30, 2026.
• Short-term working capital loans from John W. Meyer totaling $105,000 in 2024 and $66,475 in 2025, bearing 18% interest and payable on demand.
• Issuance of 257,142,858 restricted shares of common stock to six members of the Board of Directors and executive officers on February 20, 2026, valued at $77,143.
• Issuance of 20,000,000 restricted shares of common stock to CFO Squad on February 20, 2026, valued at $4,000.

Stakeholder Impact

• Existing shareholders face significant dilution due to the conversion of convertible debt into equity and the issuance of shares for services and compensation.
• Creditors and lenders may be impacted by the company's ongoing financial difficulties and defaults on certain financing agreements.
• Employees and independent business partners may be concerned about the company's going concern status and its ability to sustain operations and growth.

Next Steps

• Restore product availability through inventory financing to replenish inventory levels and recover sales volume.
• Continue to raise additional capital through equity or debt securities, factoring arrangements, and director loans to fund operations.
• Execute business plan, increase revenue, and reduce expenditures to address going concern issues.
• The company will continue to issue shares of common stock upon the conversion of outstanding convertible debt obligations.

Key Dates

Recommendation

The company exhibits significant financial distress, characterized by declining sales, persistent net losses, a substantial working capital deficit, and a going concern warning. While operational cost reductions and new e-commerce initiatives are noted, they are insufficient to offset the fundamental financial challenges and the high risk of dilution from ongoing capital raises and debt conversions. The uncertainty surrounding future financing and the ongoing legal proceedings further elevate the risk profile, making it a sell recommendation.

Keywords

Stem Cell Nutrition, Network Marketing, E-commerce Platform, Form 10-Q, Financial Statements, Going Concern, Working Capital Deficit, Convertible Debt